Results

Most recent

AMD-Neovascular

1–7 of 7 results for Neovascualar AMD Clinical Trials

Effect of Adjuvant Topical Dorzolamide-Timolol Versus Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
Jason Hsu, MD
On Demand Cases, Courses, and Papers
2020
Dual Targeting VEGF/Ang3 Surrobody in an Experimental Model of Neovascularization
Jeffrey L. Olson, MD
Annual Meeting Talks
2019
Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients With nAMD Following a Modified Manufacturing Process
Raj K. Maturi, MD
Annual Meeting Talks
2019
FIDO Study: 10-Year Outcomes of Eyes Receiving Continuous, Fixed-Interval Dosing of Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Ivan J. Suner, MD, MBA
Annual Meeting Talks
2019
Abicipar Pegol Phase 3 AMD Studies
Pravin U. Dugel, MD
Updates from the Field
2017
Brolucizumab: Will it Make a Differance
Andrew P. Schachat, MD
Updates from the Field
2018
Brolucizumab for Neovascular AMD: The 2 Year HAWK and HARRIER Results
Pravin U. Dugel, MD
Updates from the Field
2018